A detailed history of Credit Agricole S A transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Credit Agricole S A holds 6,128 shares of BMRN stock, worth $388,637. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,128
Previous 5,440 12.65%
Holding current value
$388,637
Previous $447,000 3.8%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $47,485 - $64,561
688 Added 12.65%
6,128 $430,000
Q2 2024

Aug 13, 2024

BUY
$74.43 - $92.22 $304,418 - $377,179
4,090 Added 302.96%
5,440 $447,000
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $838 - $990
-10 Reduced 0.74%
1,350 $117,000
Q4 2023

Feb 13, 2024

SELL
$76.22 - $98.51 $8,003 - $10,343
-105 Reduced 7.17%
1,360 $131,000
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $19,651 - $21,824
-231 Reduced 13.62%
1,465 $129,000
Q2 2023

Jul 31, 2023

BUY
$86.68 - $100.3 $60,329 - $69,808
696 Added 69.6%
1,696 $147,000
Q3 2021

Nov 15, 2021

SELL
$74.77 - $85.47 $104,678 - $119,658
-1,400 Reduced 58.33%
1,000 $77,000
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $89,676 - $108,828
1,200 Added 100.0%
2,400 $181,000
Q1 2019

May 14, 2019

BUY
$84.2 - $98.62 $16,840 - $19,724
200 Added 20.0%
1,200 $107,000
Q2 2018

Aug 10, 2018

BUY
$76.01 - $99.03 $76,010 - $99,030
1,000 New
1,000 $94,000
Q4 2017

Feb 13, 2018

SELL
$80.76 - $95.13 $13.7 Million - $16.1 Million
-169,520 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $2.96 Million - $3.49 Million
36,712 Added 27.64%
169,520 $15.8 Million
Q2 2017

Aug 14, 2017

BUY
N/A
132,808
132,808 $12.1 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Credit Agricole S A Portfolio

Follow Credit Agricole S A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Agricole S A, based on Form 13F filings with the SEC.

News

Stay updated on Credit Agricole S A with notifications on news.